CTLA4 and neoplasm: Accordingly, the activity of the Adeno encoded anti-CTLA-4 was confirmed when it was used in combination with a different Adenovirus vaccine vector (GAd) encoding cancer neo-antigens, whereby it broadened the repertoire of tumor-specific T cells, by enhancing the immune responses to sub-dominant epitopes and leading to better poly-specific anti-tumor immunity.